Having trouble accessing articles? Reset your cache.

Inhibiting CD36 to overcome resistance to Tykerb in HER2-positive breast cancer

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer

Inhibiting CD36, a fatty acid transporter, could treat HER2-positive breast cancer and sensitize tumors resistant to

Read the full 202 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE